Supplemental Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare Competitive Bidding Program
Supplemental Oxygen Use, Outcomes, and Spending in Patients With COPD im Medicare Competitive Bidding Program
JAMA Internal Medicine · 01.12.2024 · 184 (12) · 1457
DOI: 10.1001/jamainternmed.2024.5738 ↗Auf einen Blick
Bei COPD war das Medicare Competitive Bidding Program mit geringeren Ausgaben, aber nicht mit Veränderungen bei Sauerstoffnutzung oder klinischen Outcomes verbunden.
Fragestellung
Welcher Zusammenhang besteht zwischen der Einführung des Medicare Competitive Bidding Program 2011 und 2013 und Sauerstoffnutzung, Outcomes und Ausgaben bei COPD?
Methode
Kohortenstudie mit Difference-in-Differences-Analyse bei Medicare-Benefizient:innen mit COPD aus Gebieten mit und ohne CBP-Einführung; Datenanalyse zwischen 6. Juni 2023 und 16. August 2024.
Ergebnisse
Bei Patient:innen mit COPD zeigte sich keine differenzielle Änderung bei neuer Sauerstoffverordnung, Absetzen von Sauerstoff, Wechseln zwischen Sauerstofftypen, Gesamtmortalität, ungeplanten Krankenhausaufnahmen oder COPD-Hospitalisierungen. Die mittleren monatlichen Ausgaben sanken differenziell um $326.22 (95 %-KI −$434.76 bis −$217.68).
Schlussfolgerung der Autor:innen
Bei COPD war das CBP mit niedrigerem Aufwand verbunden, aber nicht mit differenziellen Veränderungen bei Sauerstoffnutzung oder klinischen Outcomes. Die Studie fand keine Evidenz für die laufenden Bestrebungen, Sauerstoff aus dem CBP zu entfernen.
Kernaussagen
- Keine differenzielle Änderung bei neuer Sauerstoffverordnung oder Absetzen
- Keine differenziellen Änderungen bei Mortalität oder Hospitalisierungen
- Mittlere monatliche Ausgaben sanken um $326.22
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.12.2024. Verfasst von Kevin I Duan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Medicare, Oxygen Inhalation Therapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA, NIA NIH HHS.
Themen: COPD
Abstract (Originalsprache)
Importance The Medicare Competitive Bidding Program (CBP), a policy that reduced durable medical equipment prices, was implemented starting in 2011. Legislation introduced in 2024 aims to remove supplemental oxygen from the CBP because of concerns that recent decreases in oxygen prescribing are due to lower prices set by the CBP, which may have decreased supply and, in turn, limited oxygen access for patients with chronic lung diseases. However, low-value prescribing of oxygen is also prevalent in practice, and decreased oxygen prescription rates may not have necessarily caused harm. Little is known about the association of the CBP with patient use, outcomes, or spending.
Objective
To examine the association between the 2011 and 2013 implementation of the CBP and supplemental oxygen use, clinical outcomes, and supplemental oxygen spending among patients with chronic obstructive pulmonary disease (COPD). Design, Setting, and Participants This cohort study used a difference-in-differences (DID) method to evaluate the association between implementation of the CBP and the outcomes of interest. Patients aged 65 to 100 years with COPD living in CBP areas were compared with those living in areas where the CBP was not yet or never implemented. The study included 100% fee-for-service Medicare data of beneficiaries enrolled between July 1, 2009, and December 31, 2015. The data analysis was performed between June 6, 2023, and August 16, 2024. Exposure The 2011 and 2013 implementation cycles of the Medicare CBP. Main Outcomes and Measures The primary outcomes were new prescriptions of oxygen during a 6-month period among beneficiaries with COPD and discontinuation of oxygen during a 6-month period among beneficiaries with COPD previously prescribed oxygen. Secondary outcomes included switches between oxygen types (gas, liquid, or concentrator), all-cause mortality, all-cause unplanned hospitalizations, COPD hospitalizations, and mean monthly allowed charges (total spending) over a 6-month period. The analysis was performed using the Callaway-Sant’Anna method, a dynamic DID model for policies with staggered implementation.
Results
Among 5 753 308 Medicare beneficiaries with COPD (mean [SD] age, 79.2 [8.4] years; 55.1% female), 25.9% received supplemental oxygen for at least one 6-month period during the study. The CBP was not associated with differential changes in new oxygen prescribing (DID estimate, −0.19 percentage points; 95% CI, −2.45 to 2.08 percentage points) or oxygen discontinuations (DID estimate, −0.77 percentage points; 95% CI, −8.15 to 6.60 percentage points). Similarly, differential changes were not observed in the secondary outcomes of oxygen switches (DID estimate, −0.04 percentage points; 95% CI, −0.44 to 0.37 percentage points), all-cause mortality (DID estimate, 0.16 percentage points; 95% CI, −7.52 to 7.84 percentage points), all-cause unplanned hospitalizations (DID estimate, −0.20 percentage points; 95% CI, −10.94 to 10.53 percentage points), or COPD hospitalizations (DID estimate, −0.04 percentage points; 95% CI, −2.57 to 2.48 percentage points). Differential changes were observed for mean monthly allowed charges (DID estimate, −$326.22; 95% CI, −$434.76 to −$217.68). Conclusions and Relevance In this study, among beneficiaries with COPD, the Medicare CBP was associated with differentially lower spending but not differential changes in oxygen use or clinical outcomes. This study did not find evidence supporting ongoing policy efforts to remove supplemental oxygen from the CBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada.
- Legacy for Airway Health, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.
- Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington School of Medicine, Seattle.
- Division of General Internal Medicine, University of Washington School of Medicine, Seattle.
- Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
- Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle.
Förderung
- HSRD VA
- NIA NIH HHS
Zitieren
APA
Duan, K. I., Obara, E., Wong, E. S., Liao, J. M., Sabbatini, A. K., Donovan, L. M., Spece, L. J., Feemster, L. C., & Au, D. H. (2024). Supplemental Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare Competitive Bidding Program. JAMA Internal Medicine, 184(12), 1457. https://doi.org/10.1001/jamainternmed.2024.5738
Vancouver
Duan KI, Obara E, Wong ES, Liao JM, Sabbatini AK, Donovan LM, et al. Supplemental Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare Competitive Bidding Program. JAMA Internal Medicine. 2024;184(12):1457. doi:10.1001/jamainternmed.2024.5738
BibTeX
@article{Duan2024,
author = {Duan, Kevin I and Obara, Emmi and Wong, Edwin S and Liao, Joshua M and Sabbatini, Amber K and Donovan, Lucas M and Spece, Laura J and Feemster, Laura C and Au, David H},
title = {Supplemental Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare Competitive Bidding Program},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {12},
pages = {1457},
doi = {10.1001/jamainternmed.2024.5738}
}
EUVIMED